STOCK TITAN

LifeStance Health Group (LFST) Stock News

LFST NASDAQ

LifeStance Health Group reports developments as a Nasdaq-listed provider of virtual and in-person outpatient mental healthcare. The company serves children, adolescents and adults through psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy.

Recurring news themes include quarterly operating results, visit volumes, clinician productivity, center-level margin trends, cash flow, debt and capital allocation. Company updates also cover secondary common stock offerings by selling stockholders, share repurchase activity, investor conference presentations, executive and board changes, and corporate-status announcements tied to its outpatient mental health services business.

Rhea-AI Summary

LifeStance Health Group (Nasdaq: LFST) priced a secondary public offering of 45,000,000 common shares sold by certain existing stockholders. The public offering price is $13.12 per share. Selling stockholders will receive all proceeds; LifeStance is not selling shares and will receive no proceeds.

LifeStance also agreed to repurchase 2,000,000 shares from the underwriters at the price the underwriters pay selling stockholders. The repurchase depends on completion of the offering, but the offering does not depend on the repurchase. Both transactions are expected to close on or about November 12, 2026, subject to customary closing conditions. Underwriters will receive no compensation for shares purchased by LifeStance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
-
Rhea-AI Summary

LifeStance Health Group (Nasdaq: LFST) announced that certain stockholders intend to offer 45,000,000 shares of its common stock in a secondary public offering. The selling stockholders will receive all proceeds; LifeStance is not selling shares and will receive no proceeds.

The company also authorized a concurrent 2,000,000-share repurchase from the underwriters, subject to completion of the offering and customary conditions. Its purchase price per share will equal the price the underwriters pay the selling stockholders. The offering is not conditional on the repurchase. Barclays and J.P. Morgan are underwriting the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
-
Rhea-AI Summary

LifeStance Health Group (Nasdaq: LFST) reported third-quarter 2026 revenue of $455.9 million and raised its full-year financial outlook. Revenue rose 25% year over year, while net income increased to $22.4 million from $1.1 million. Operating income reached $33.1 million, versus $7.4 million.

Visits increased 17% to 2.7 million, and the clinician base grew 11% to 8,863. Adjusted EBITDA, a supplemental earnings measure, rose 70% to $68.4 million. Operating cash flow was $37.0 million, with free cash flow of $22.4 million.

LifeStance now expects 2026 revenue of $1.741 billion to $1.761 billion, Center Margin of $599 million to $613 million, and adjusted EBITDA of $242 million to $250 million. Center Margin measures operating income before depreciation, amortization and general administrative expenses. Fourth-quarter revenue is expected to be $446 million to $466 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
Rhea-AI Summary

LifeStance Health (LFST) is expanding access to specialty depression treatments as separate patient analyses show reductions in symptoms and suicidal ideation.

Among 258 patients receiving esketamine (Spravato), 74% experienced a clinically meaningful reduction in depression severity after 12 weeks. The share reporting suicidal ideation nearly every day fell from 13% before treatment to 2% afterward. Among 355 patients receiving transcranial magnetic stimulation (TMS), 61% experienced a clinically meaningful reduction after at least 30 treatment sessions; nearly daily suicidal ideation fell from 13% to 6%. Both analyses involved patients with treatment-resistant depression and used the Patient Health Questionnaire (PHQ-9) to measure symptom severity. These observational results describe the patients analyzed and do not guarantee individual outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
none
-
Rhea-AI Summary

LifeStance Health Group (LFST) will release its third quarter 2026 earnings before the market opens on November 5, 2026.

The company will discuss results on a live conference call at 8:30 a.m. Eastern Time that day. A webcast and subsequent replay will be available on its investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.09%
Tags
conferences earnings date
-
Rhea-AI Summary

LifeStance Health (LFST) released a survey finding that fear of becoming social media content limits public self-expression for 47% of respondents.

Among Gen Z respondents, concerns about being recorded and shared online affect enjoyment of the present moment for 74% and the desire to leave home or attend events for 72%, compared with 52% and 48% across all respondents. Gen Z respondents also reported weekly negative effects on mood (47%), confidence and self-esteem (44%), sleep (43%) and anxiety (42%). Across generations, 20% have avoided social gatherings with friends and 19% have avoided bars or nightlife.

One in five respondents believe therapy can help address this social anxiety; 19% would consider therapy if these concerns began affecting daily life. Dynata conducted the survey for LifeStance in July 2026, collecting responses from 1,000 U.S. adults ages 18 and up.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
Rhea-AI Summary

LifeStance Health Group (LFST) priced a secondary public offering of 22,250,000 common shares at $12.35 per share.

All proceeds will go to selling stockholders; the company is not issuing shares and will receive no proceeds. LifeStance agreed to repurchase 2,000,000 shares from the underwriter, conditional on the offering’s completion, with both transactions expected to close on or about September 11, 2026. Barclays is acting as sole underwriter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary

LifeStance Health Group (LFST)/b) announced that certain existing stockholders plan to sell 22,250,000 shares of its common stock in a secondary offering under an effective shelf registration statement.The selling stockholders will receive all proceeds and the company will not sell any shares or receive any proceeds. LifeStance has also authorized a concurrent repurchase of 2,000,000 shares from the underwriter at the same per-share price paid to the selling stockholders, subject to completion of the offering and customary conditions. Barclays is acting as the sole underwriter, and the offering will be made only by means of a prospectus and related prospectus supplement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary

LifeStance Health Group (NASDAQ: LFST) announced that its management will present at two investor conferences in September 2026. The CFO, Ryan McGroarty, will present at the 2026 Jefferies Healthcare Services and Technology Conference in Nashville on September 14, while CEO Dave Bourdon will speak at the 24th Annual Morgan Stanley Healthcare Conference in New York on September 15.

Both presentations will be webcast live, with live and replay access available through the Events and Presentations section of the LifeStance Health investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.30%
Tags
conferences
Rhea-AI Summary

LifeStance Health (LFST) released results from a survey of 1,000 women born between 1960-1990 who are experiencing or suspect perimenopause or menopause. The survey highlights that 33% did not know perimenopause can cause mental health symptoms, while many report severe anxiety (66%) and depression (54%).

According to LifeStance, 83% of respondents who tried therapy and 82% who tried prescribed medications such as antidepressants or estrogen found them helpful. Nearly half (47%) believe mental healthcare should be standard in perimenopause care, and 59% would be more likely to seek it if they knew it could significantly improve symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
none

FAQ

What is the current stock price of LifeStance Health Group (LFST)?

LifeStance Health Group (LFST) last closed at $14.17.

What is the market cap of LifeStance Health Group (LFST)?

The market cap of LifeStance Health Group (LFST) is approximately $5.4B.